These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35252267)

  • 21. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year results of intravitreal conbercept in treatment-naïve subjects with polypoidal choroidal vasculopathy.
    Ye LH; Cai Y; Shi X; Wong IYH; Qu JF; Zhao MW; Ying X; Li XX
    Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1455-1462. PubMed ID: 33146832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
    Silva R; Arias L; Nunes S; Farinha C; Coimbra R; Marques JP; Cachulo ML; Figueira J; Barreto P; Madeira MH; Pires I; Sousa JC; Distefano L; Rosa P; Carneiro Â; Vaz-Pereira S; Meireles A; Cabrera F; Bures A; Mendonça L; Fernandez-Vega-Sanz A; Barrão S; Koh A; Cheung CMG; Cunha-Vaz JG; Murta J;
    Ophthalmologica; 2022; 245(1):80-90. PubMed ID: 34348351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY: A 3-YEAR FOLLOW-UP.
    Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
    Retina; 2018 Oct; 38(10):2001-2009. PubMed ID: 28816730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M; Matsumoto H; Mimura K; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Initial vs. Delayed Photodynamic Therapy in Combination With Conbercept for Polypoidal Choroidal Vasculopathy.
    Sun Z; Gong Y; Yang Y; Huang Y; Yu S; Pei J; Lin B; Zhou R; Li Y; Li Y; Zhang J; Liu X
    Front Med (Lausanne); 2021; 8():791935. PubMed ID: 35223882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study.
    Sakamoto S; Takahashi H; Inoue Y; Arai Y; Inoda S; Kakinuma N; Fujino Y; Tanabe T; Kawashima H; Yanagi Y
    Clin Ophthalmol; 2018; 12():1137-1147. PubMed ID: 29970955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Polyp Regression on 2-year Outcomes of Intravitreal Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal Choroidal Vasculopathy.
    Morizane-Hosokawa M; Morizane Y; Kimura S; Shiode Y; Hirano M; Doi S; Toshima S; Hosogi M; Fujiwara A; Shiraga F
    Acta Med Okayama; 2018 Aug; 72(4):379-385. PubMed ID: 30140086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
    Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.
    Marques JP; Farinha C; Costa MÂ; Ferrão Â; Nunes S; Silva R
    BMJ Open; 2017 Aug; 7(8):e015785. PubMed ID: 28851779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
    Singh SR; Sahoo NK; Goud NR; Chhablani J
    Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review.
    Wang Y; Shen M; Cheng J; Sun X; Kaiser PK
    J Ophthalmol; 2020; 2020():4924053. PubMed ID: 32855818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S; Matsumiya W; Keiko O; Miki A; Nakamura M; Honda S
    Jpn J Ophthalmol; 2019 Jan; 63(1):100-108. PubMed ID: 30406511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hosokawa MM; Ouchi C; Shiode Y; Kimura S; Matoba R; Morita T; Morizane Y
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; ():. PubMed ID: 38625447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient.
    Choo HG; Lee JH; Oh HS; Kim SH; You YS; Kwon OW
    BMC Ophthalmol; 2021 Feb; 21(1):94. PubMed ID: 33602156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement.
    Hirakata T; Fujinami K; Watanabe K; Sasaki M; Noda T; Akiyama K
    Clin Ophthalmol; 2016; 10():969-77. PubMed ID: 27307700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.